Endocrine Abstracts (2009) 20 P27

Autoantibody screening of autoimmune gastrointestinal disorders in patients with autoimmune Addison disease

Peter Kentos, Mikulas Pura & Peter Vanuga


Department of Endocrinology, National Institute of Endocrinology and Diabetology, Lubochna, Slovakia.


Backrgound: Coexistent gastrointestinal pathology might alter hydrocortisone (HCT) and levothyroxine (LT4) absorption and gut transit times.

Aims: To screen patients with autoimmune Addison disease for the presence of serological markers of autoimmune gastrointestinal disorders, to compare doses of HCT and LT4 in patients with positive autoantibodies to those of patients without signs of autoimmune gastroenteropathy.

Subjects and methods: Of 62 patients with autoimmune Addison disease were investigated. Autoantibodies against tissue transglutaminase (t-TGA) were measured by CLIA, autoantibodies against gastric parietal cells (PCA) were measured by an indirect immunofluorescence method.

Results: Mean daily doses of HCT and LT4 were higher in patients (n=13) with positive PCA and/or t-TGA – HCT 22.5±5.9 vs 19.0±2.9 mg (P>0.05), HCTBW 0.37±0.08 vs 0.32±0.04 mg/kg (P<0.05), HCTBSA 13.9±3.0 vs 11.8±1.3 mg/m2 (P<0.05); LT4 103.8±21.4 vs 87.9±28.0 μg (P>0.05), LT4BW 1.75±0.46 vs 1.47±0.55 μg (P>0.05), LT4BSA 65.4±14.3 vs 54.7±16.9 μg/m2 (P>0.05). Conlusions

Our results suggest for high prevalence of serological markers of autoimmune gastrointestinal disorders in APS. Already state of PCA- and/or t-TGA positivity may underly the requirement of higher HCT and LT4 doses. Measurement of serum PCA and t-TGA should be part of the routine autoantibody screening and the diagnostic work up in Addison or APS patients with unexplained high HCT or LT4 doses.

Article tools

My recent searches

No recent searches.